MYC and hematologic disorder: MYC was also targeted by use of the bromodomain inhibitor, JQ1, due to its efficacy in other models of hematological malignancies.35 The increase in glucose uptake induced by anti-IgM stimulation was blocked by ibrutinib, idelalisib, and JQ1 (Figure 4A).